Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...
Why Samsung Still Reigns Supreme. Samsung has long been known for quality design of electronics. The company has some of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback